References
- HonerjägerPPharmacology of bipyridine phosphodiesterase III inhibitorsAm Heart J19911216 Pt 2193919441852089
- SkoylesJRSherryKMPharmacology, mechanisms of action and uses of selective phosphodiesterase inhibitorsBr J Anaesth19926832933021547054
- KimataSHirosawaKKasanukiH[Clinical evaluation of E-1020 injection for acute heart failure. Study of acute effects by single intravenous infusion and intravenous drip]Jpn Clin Exp Med199269722602274 Japanese
- MonradESBaimDSSmithHSLanoueASMilrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failureCirculation1986733 Pt 2III168III1743510773
- AdachiHTanakaHEffects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failureJ Cardiovasc Pharmacol19972967637719234657
- RathmellJPPrielippRCButterworthJFA multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgeryAnesth Analg19988646836909539583
- OrimeYShionoMHataHEffects of phosphodiesterase inhibitors after coronary artery bypass graftingJpn Circ J199963211712210084374
- TakaokaHTakeuchiMOdakeMComparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heartJ Am Coll Cardiol19932225986068335835
- AdachiHKamataSKodamaKNagakuraTVasorelaxant effect of a phosphodiesterase 3 inhibitor, olprinone, on isolated human radial arteryEur J Pharmacol20003961434710822053
- GuarracinoFLapollaFCarielloCTarget controlled infusion: TCIMinerva Anestesiol200571633533715886597
- ShortTGLimTATamYHProspective evaluation of pharmacokinetic model-controlled infusion of propofol in adult patientsBr J Anaesth19967623133158777118
- Guidance for industry: population pharmacokineticsSilver Spring: United States Food and Drug Administration [updated 1999 Feb 1]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdfAccessed October 21, 2013
- HookerACStaatzCEKarlssonMOConditional weighted residuals (CWRES): a model diagnostic for the FOCE methodPharm Res200724122187219717612795
- TsubokawaTIshizukaSFukumotoKUenoKYamamotoKPopulation pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypassJ Anesth201327224325023090059
- WietaschJKScholzMZinserlingJThe performance of a target-controlled infusion of propofol in combination with remifentanil: a clinical investigation with two propofol formulationsAnesth Analg2006102243043716428538
- PassotSServinFAllaryRTarget-controlled versus manually-controlled infusion of propofol for direct laryngoscopy and bronchoscopyAnesth Analg200294512121216 table of contents11973192
- De CastroVGodetGMenciaGRauxMCoriatPTarget-controlled infusion for remifentanil in vascular patients improves hemodynamics and decreases remifentanil requirementAnesth Analg2003961333812505919
- VermeyenKMHoffmannVLSaldienVTarget controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic modelBr J Anaesth200390218318812538375
- SugiokaMItoMMasuokaHIdentification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymesNaunyn Schmiedebergs Arch Pharmacol199435032842937824045
- AraiTKamishimaKTerauchiT[Effects of olprinone hydrochloride in patients undergoing off-pump coronary artery bypass grafting]Masui2006552158163 Japanese16491891